Avascular Necrosis Market Size - Global Industry, Share, Analysis, Trends and Forecast 2024 - 2032

Market Drivers

• Rising incidence of osteonecrosis globally
• Growing market for non-invasive treatment
• Increasing number of medicines approvals from regulatory agencies
• Rising proportion of product offerings by market participants

Market Restraints

• High cost of current therapies
• Availability of alternative methods for treatment

Market Opportunities

• Increasing government support for R&D
• The growing popularity of the non-invasive approach
• Increasing adoption of mesenchymal stem cell therapy and gene therapy for bone regeneration

Avascular Necrosis Market Report Coverage

Avascular Necrosis Market Insights

The expanding geriatric population raises the prevalence of avascular necrosis globally, as well as the growing desire for non-invasive intervention in addition to technical improvements for improved osteonecrosis treatment, are the primary major factors in the avascular necrosis market value. The growing incidences of osteonecrosis worldwide, as well as the increasing need for non-invasive therapy and reliance on operations to cure avascular necrosis, are likely to accelerate market expansion. Furthermore, the growing prevalence of the non-invasive approach to avascular necrosis hospitalization will pave the road for market expansion. Besides that, the prevalence of osteonecrosis is rising as a result of some of the common causes of the disease. As a result, the desire for osteonecrosis therapy is increasing, and the avascular necrosis market is expected to rise exponentially throughout the projected timeframe.

Furthermore, the rise in global alcohol use is a major factor driving the growth of the market. According to a survey conducted by the National Institute on Alcohol Abuse and Alcoholism, the number of people drinking alcohol in the United States has grown tremendously in recent years. According to the industry analysis, the proportion of female alcohol consumers has more than doubled. Alcohol misuse causes aberrant lipid metabolism, which is a substantial risk factor for alcohol-induced avascular necrosis, resulting in a surge of avascular necrosis market major trends and prospects.

Avascular Necrosis Market Segmentation

The worldwide market for avascular necrosis is split based on disease type, treatment type, route of administration, diagnosis, sales channel, and geography.

Avascular Necrosis Disease Types

• Traumatic Avascular Necrosis
• Non-traumatic Avascular Necrosis

According to avascular necrosis industry analysis, the non-traumatic avascular necrosis segment is predicted to capture a significant share of the market. These rises are the result of metabolic bone diseases, increased consumption of alcohol, metabolic bone diseases, and other ailments. Non-traumatic avascular necrosis of the femoral head is the major cause of impairment in young folks, resulting in significant health care costs. The growing usage of testosterone and alcohol intake in the latest days has considerably increased the frequency of femoral head necrosis.

Avascular Necrosis Treatment Types

• Drug Type
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
    • Naproxen Sodium
    • Ibuprofen
  • Osteoporosis Drugs
  • Cholesterol Lowing Drugs
  • Blood Thinners
  • Others
• Therapy
  • Physical Therapy
  • Exercises
  • Gene Therapy and Surgery

In terms of treatment type, the cholesterol-lowering drugs segment held the largest market share in 2023. This growth is related to the fact that lowering the quantity of cholesterol as well as fat within circulation may help avoid arterial obstructions that might contribute to avascular necrosis. Besides that, the nonsteroidal anti-inflammatory drugs segment is predicted to rise at a significant rate in the market over the next few years. These medications aid in the relief of pain associated with avascular necrosis of the hip. Furthermore, this sector is subdivided into ibuprofen and naproxen sodium.

Avascular Necrosis Route of Administrations

• Oral
• Parenteral

The oral segment is predicted to develop significantly in the avascular necrosis (AVN) market due to the increased use of nonsteroidal anti-inflammatory medications (NSAIDs), bisphosphonates, cholesterol-lowering medicines, and anticoagulants for early-stage AVN therapy. When compared to parenteral choices, oral drugs are more convenient to administer, have more patient compliance, and are less expensive. Furthermore, the rising preference for non-invasive treatment options, as well as advancements in formulations with improved bioavailability, is driving industry expansion. With a rise in AVN cases linked to steroid use and lifestyle factors, oral therapies remain the favored option for symptom management and disease progression control, maintaining their long-term market dominance.

Avascular Necrosis Diagnosis

• MRI
• CT Scan
• Biopsy
• PET and X-ray

The MRI segment has grown significantly in the market because of its improved diagnostic accuracy in detecting early-stage bone necrosis. Unlike X-rays or CT scans, MRI can detect AVN in its early stages, before structural damage occurs, allowing for timely intervention. The growing understanding of early detection, combined with the rising prevalence of AVN induced by corticosteroid usage and excessive alcohol use, has raised the demand for MRIs. Furthermore, advancements in imaging technology, such as high-resolution and 3D MRI, have improved the accuracy of bone injury diagnosis. The increasing availability of MRI equipment in hospitals and diagnostic centers around the world is driving market expansion, with MRI becoming the main diagnostic approach for AVN identification and monitoring.

Avascular Necrosis Sales Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

According to the avascular necrosis market forecast, the hospital pharmacy segment is expected to increase significantly in the approaching years. The increasing demand for non-invasive treatment and reliance on surgery to cure osteonecrosis is driving segment expansion. Furthermore, improving healthcare infrastructure by regional governments, as well as rising hospitalization choices, is propelling the market forward.

Avascular Necrosis Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of LATAM

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Avascular Necrosis Market Regional Analysis

North America is reported to be considerably responsible for revenue shares, accounting for more than one-third of the global avascular necrosis market, due to its higher acceptance of cutting-edge therapeutic approaches and greater concentration of relevance of avascular necrosis in individuals. In this region, the United States has seen a greater acceptance of avascular necrosis approach. The growing senior population, together with the public emphasis on the medical problem and diagnostics in this region, is expected to propel the expansion of the avascular necrosis market. Moreover, North America is projected to dominate the avascular necrosis market owing to the growing number of aggressive investment tactics adopted by industry participants.

Avascular Necrosis Market Players

Some of the top avascular necrosis companies offered in our report include Teva Pharmaceuticals Industries Ltd., GSK, Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., Bayer AG, Alkem Labs, Novartis AG, Solara Active Pharma Sciences Limited., Rochem International, Inc., and Dwarkesh Pharmaceuticals Private Limited.